Prostate cancer remains a significant health concern for men globally, and the search for effective and targeted therapies continues. In a recent study, researchers from Guizhou Medical University identified a new class of 4-trifluoromethylquinoline derivatives that demonstrated potent anti-prostate cancer activity by inhibiting the serum/glucocorticoid-regulated kinase 1 (SGK1).

Protein phosphatase 2A (PP2A) is a key serine/threonine phosphatase that controls various signaling pathways and influences cancer development and treatment outcomes.

Triple-negative breast cancer is an especially challenging subtype characterized by the absence of key receptors, limiting the effectiveness of many standard breast cancer treatments.

Aiming to develop a systemic therapy for advanced refractory cancers, researchers have designed a novel oncolytic adenovirus that selectively targets and kills cancer cells expressing mesothelin.

Alchemab Therapeutics Ltd. has entered into a licensing agreement with Eli Lilly and Co. for ATLX-1282, Alchemab’s first-in-class IND-ready program targeting a novel receptor and mechanism for amyotrophic lateral sclerosis (ALS) and other neurodegenerative conditions.

Odylia Therapeutics Inc. has announced it is working under a codevelopment partnership with the NPHP1 Family Foundation to create an AAV-based gene replacement therapy for retinal dystrophy caused by mutations in the NPHP1 (nephrocystin-1) gene.